Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH5 | P11766 | 1/20 | 0.75 |
| ▸ | RPA1 | P27694 | 1/20 | 0.64 |
| ▸ | ATM | Q13315 | 1/20 | 0.64 |
| ▸ | XDH | P47989 | 9/20 | 0.59 |
| ▸ | TP53 | P04637 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HPGDS | O60760 | 1/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9984638 | 0.89 | ADH5 (0.95) | ADH5RPA1ATMXDHTP53 | |
| SCHEMBL16645309 | 0.78 | ADH5 (0.75) | ADH5RPA1ATMXDHTP53 | |
| SCHEMBL14347139 | 0.78 | ADH5 (0.75) | ADH5RPA1ATMXDHTP53 | |
| SCHEMBL2645811 | 0.78 | ADH5 (0.75) | ADH5RPA1ATMXDHTP53 | |
| SCHEMBL1248039 | 0.78 | ADH5 (0.75) | ADH5RPA1ATMXDHTP53 | |
| SCHEMBL2667739 | 0.78 | ADH5 (0.75) | ADH5RPA1ATMXDHTP53 | |
| SCHEMBL467316 | 0.78 | ATM (1.00) | ADH5RPA1ATMXDHTP53 | |
| SCHEMBL1777649 | 0.78 | ADH5 (0.75) | ADH5RPA1ATMXDHTP53 | |
| SCHEMBL1249470 | 0.78 | XDH (0.69) | ADH5RPA1ATMXDHTP53 | |
| SCHEMBL5891983 | 0.77 | ADH5 (0.79) | ADH5RPA1ATMXDHTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1702919-B1 | NOVEL 2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE | MSD KK (JP) | 2012-05-30 | — | — | EP | disclosed |
| US-7728025-B2 | 2-heteroaryl-substituted benzimidazole derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-06-01 | — | — | US | disclosed |
| US-20080070928-A1 | Novel 2-Heteroaryl-Substituted Benzimidazole Derivative | MSD K.K. (JP) | 2008-03-20 | — | — | US | disclosed |
| EP-1702919-A1 | NOVEL 2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070928-A1 | Novel 2-Heteroaryl-Substituted Benzimidazole Derivative | GCK, GCKR, HK1 | ADH5 810/4885RPA1 3914/4885ATM 896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.